Latest news
Phase III Trial: 8-Week Bemnifosbuvir/Ruzasvir Regimen Matches Standard Hepatitis C Therapy - Medical DialoguesMedical Dialogues · Fri, 07 Aug 2026 15:15:57 GMTVedanta secures $60 million ahead of pivotal Phase III C. difficile data - The Pharma LetterThe Pharma Letter · Fri, 07 Aug 2026 10:43:59 GMTVedanta gets $60M to finish Phase 3 for C. diff microbiome therapy - Endpoints NewsEndpoints News · Thu, 06 Aug 2026 11:00:00 GMTAtea's hepatitis C combination meets non-inferiority bar, clears path to regulatory filing - AllSciAllSci · Wed, 29 Jul 2026 09:05:26 GMTAtea reports positive topline results in Phase III hepatitis C study - Clinical Trials ArenaClinical Trials Arena · Wed, 29 Jul 2026 07:00:00 GMTAtea’s hepatitis C asset matches Gilead’s Epclusa in phase 3 trial - Fierce BiotechFierce Biotech · Tue, 28 Jul 2026 13:08:59 GMTAbelZeta Receives FDA Clearance of Registrational Phase II Trial for C-CAR168 in Refractory Lupus Nephritis - PR NewswirePR Newswire · Mon, 27 Jul 2026 07:00:00 GMT